Less Than 10%: The Capital Profile Every CFO Should See Before Stage 2 Commits
In most corporate venturing portfolios, less than 10% of total lifetime venture capital is deployed before the decision to scale. That early slice sets the direction for everything that follows — and it is almost never subjected to a structured external diagnostic.
Less than 10%. That is how much of a corporate venture's total lifetime capital is typically deployed before the decision to scale.
The ideation work, the hypothesis sprint, the initial customer validation — all of it combined represents less than a tenth of what the venture will eventually consume. The Stage 3 go-to-market buildout and Stage 4 scaling represent 65–80% of total lifetime capital. Everything else follows from the direction that early slice sets.
Most organizations understand this in the abstract. Almost none apply it to their diagnostic process.
The Stage-by-Stage Capital Profile
In a corporate venturing portfolio with $10M of total lifetime exposure, the capital allocation by stage looks approximately like this:
- Stage 0 (Ideation): $100K–$200K — workshops, concept shaping, desk research.
- Stage 1 (Hypothesis): $300K–$500K — structural diagnostic and early customer work.
- Stage 2 (Proving): $1M–$2M — MVP, pilots, initial market evidence.
- Stage 3 (Go-to-Market): $3M–$4M — GTM buildout, sales, marketing.
- Stage 4 (Scale/Mezzanine): $3.5M–$5.5M — scaling, integration, or spinout.
<1%
The VAD sprint fee — $15,000–$20,000 — represents 4–6% of the Stage 1 budget and less than 1% of total venture exposure at that scale. It is the structured gate inserted at Stage 1 before the Stage 3 commitment locks in.
What Most Organizations Spend Stage 1 On
The problem is not the amount spent at Stage 1. It is how it is spent.
Most organizations allocate Stage 1 budget to activities that generate ideas and build internal conviction: innovation workshops, design sprints, early product concepts, executive alignment sessions. These are necessary activities. What they almost never include is a rigorous external diagnostic of the organizational host: whether the Resources, Processes, and Priorities of the company that will incubate this venture are structurally compatible with what the venture actually requires.
So the Stage 1 budget produces a hypothesis with strong internal conviction and no external stress test. The Stage 2 MVP builds on that hypothesis. The Stage 3 GTM commits to the direction the MVP pointed. By the time Stage 3 capital is locked in, the structural verdict that should have been issued at Stage 1 is now the post-mortem.
The CFO Argument
The Venture Architecture Diagnostic is not a consulting expense. It is a capital allocation diagnostic — a structured gate inserted at Stage 1 before a potential $3–4M Stage 3 commitment.
If the VAD produces a GO verdict, the Stage 3 commitment proceeds with a 20–30 page evidence base and a bias-calibrated financial model. If it produces a PIVOT, the commitment is restructured before the wrong product is built at scale. If it produces a WRONG COMPANY verdict, the Stage 3 capital is redirected toward a partnership or spin-out rather than absorbed by a host that cannot execute what the venture requires. If it produces a NO-GO, the commitment is avoided entirely — and the capital returns to the portfolio rather than confirming, at ten times the cost, what the Stage 1 diagnostic already showed.
The Governance Case
Boards are not demanding diagnostics because ventures got riskier. They are demanding them because activity masquerading as governance finally got expensive enough to notice.
For most of the last decade, corporate innovation ran on a volume model: more ideas in the funnel, more shots on goal, more learning by doing. The logic was sound. The governance was not — because “test and learn” almost never included a structured decision about whether the organizational host could actually execute what the venture required. That gap is now visible on balance sheets.
The diagnostic is back — not as a consulting artifact, but as governance infrastructure. A bounded, time-limited, verdict-producing gate before the expensive phases lock in. What changed is not that ventures got riskier. What changed is that boards got less willing to fund risk without an explicit diagnostic gate at Stage 1.
The question is not whether the VAD is worth the cost. The question is whether the Stage 3 commitment is worth proceeding without one.
Take the 5-Question RPP Readiness Check
Five minutes. A directional read on whether your organizational host is structurally positioned to execute what your venture requires. No scoring language. No verdict. The question that tells you whether you need one.
Take the Check →